Collectively, the effects of SGLT2 inhibitors on diabetes-induced cognitive impairment and stroke may be attributed to the systemic effects of glycemic control, anti-inflammation, and antioxidative effects. This evidence concerns the gene SLC5A2 and diabetes mellitus.